This indicated that although ER expression itself was the main predictor of endocrine therapy response, the expression of AGR2 was closely related to the resistance of ER positive breast cancer patients to endocrine drugs (95), and serum AGR2 has potential availability as a biomarker for noninvasive early detection of tamoxifen resistance by ELISA. The gene discussed is AGR2; the disease is breast cancer.